|
Factor
|
Univariable
| |
Multivariablea
| |
|---|
| |
(IC95%)
|
P-value
|
(IC95%)
|
P-value
|
|---|
|
Baseline CD4
|
|
≥ 200 cells/mm3
|
1
| |
1
| |
|
< 200 cells/mm3
|
1.375 (0.332;5.694)
|
0.661
|
5.547 (1.348;22.821)
|
0.018
|
|
Gender
|
|
Male
|
1
| | | |
|
Female
|
0.242 (0.052; 1.118)
|
0.069
| | |
|
Age (Year)
|
|
38–44
|
1
| |
1
| |
|
32–18
|
3.87 (1.336;11.212)
|
0.013
|
2.808 (1.13;6.98)
|
0.026
|
|
37–32
|
1.256 (0.305;5.169)
|
0.752
|
1.061 (0.292; 3.862)
|
0.928
|
|
Site of tuberculosis
|
|
Pulmonary
|
1
| |
1
| |
|
Disseminated
|
1.173 (0.285; 4.836)
|
0.825
|
1.531 (0.468; 5.01)
|
0.482
|
|
Extrapulmonary
|
4.275 (1.122; 16.285)
|
0.033
|
6.431 (1.566; 26.408)
|
0.010
|
|
Ethnicity
|
|
White
|
1
| | | |
|
Black
|
2.544 (0.603; 10.737)
|
0.204
| | |
|
Mulattoes
|
1.376 (0.283; 6.705)
|
0.692
| | |
|
Efavirenz dose
|
|
600 mg
|
1
| |
1
| |
|
800 mg
|
3.187 (0.901;11.266)
|
0.072
|
3.505 (1.04;11.817)
|
0.043
|
|
HIV-1 viral load
|
|
Detectable
|
1
| | | |
|
Undetectable
|
2.348 (1.228;4.489)
|
0.010
| | |
|
Follow-up CD4 cells/mm3
| | | | |
|
≥200 cells/mm3
|
1.003 (1.001; 1.005)
|
0.002
|
1.006 (1.003; 1.009)
|
<0.001
|
|
<200 cells/mm3
|
1.004 (0.996; 1.1014)
|
0.312
|
1.011 (1.002; 1.02)
|
0.016
|
|
Follow-up %HLA-DR+/CD3+ T cells
|
0.994 (0.975; 1.014)
|
0.559
| | |
|
Follow-up % CD8+/38+ T cells
|
0.998 (0.972; 1.024)
|
0.851
| | |
|
Follow-up IFN-γ plasmatic
|
0.989 (0.946; 1.033)
|
0.61
| | |
-
aThe predictors in the PPD antigen final model are as follows: Baseline CD4, Age, Site of tuberculosis, Efavirenz dose, Follow-up CD4 ≥ 200 cells/mm3 and Follow-up CD4 < 200 cells/mm3
